Dupilumab in children and adolescents with atopic dermatitis, a 52-week real-life experience: first report in Colombia

Dupilumab in children and adolescents with atopic dermatitis, a 52-week real-life experience: first report in Colombia

Atopic dermatitis (AD) is a chronic inflammatory disease characterized by relapsing eczema and pruritus. Recently, dupilumab has shown to be safe and improve symptoms of moderate to severe AD in adolescents up to 52 weeks, however, very few Latin American patients were included, so comprehensive re...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniela Meléndrez Vásquez, María Fernanda Ordoñez-Rubiano, Daniela Marín-Acevedo
Format: Article
Language:English
Published: Asociación Colombiana de Dermatología y Cirugía Dermatológica 2024-10-01
Series:Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Subjects:
Biológico
Dermatitis atópica
Dupilumab
Eczema
Online Access:https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1743
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items